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Objectives: To explore the clinical and serological course of fertile women with 
positive aPL, and the factors and therapeutic implications associated with aPL 
negativization. 
Methods:  Retrospective study including 105 women with a positive aPL serology 
between 1995 and 2013 attending the obstetric autoimmune pathology clinic of a 
tertiary-facility. Patients were classified into 3 groups: patients with primary 
antiphospholipid syndrome (pAPS, 49), patients with a positive serology for aPL, not 
meeting clinical criteria (42) and patients with systemic lupus erythematosus and a 
positive aPL serology (14). They were also classified, according to the serological aPL 
evolution: persistently negative aPL, transiently positive serology and persistently 
positive serology according to established criteria.  
Results: After a mean follow-up of 114.4 ± 37.2 months, 59% patients had persistently 
negative antibodies, while 25.7% patients presented persistently positive aPL serology. 
Multivariate analysis confirmed that smoking (OR 4, 95%CI 1.45-11.08, p=0.008) was 
an independent risk factor for positive persistence. Persistent positivity, as well as a 
higher antibody load was associated with higher risk for further pregnancy morbidity. In 
29 patients, with persistently negative serology who were asymptomatic, treatment with 
low-dose aspirin was discontinued. No clinical events related to APS were reported 
after treatment withdrawal, during the 40.95 months of follow-up. 
Conclusions: A significant proportion of fertile women with aPL antibodies became 
negative during follow-up. Tobacco use and the number of positive antibodies are 
associated with persistently positive serology. Patients with persistently positive aPL 
serology suffer more obstetric complications. Treatment withdrawal might be safe in 
selected patients. 
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Antiphospholipid antibodies (aPL) are a group of autoantibodies that bind to negatively 
charged phospholipids, phospholipid-binding proteins or both [1]. The most commonly 
detected antibodies are lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and 
anti B2 glycoprotein I antibodies (aB2GPI), being the role of other non-criteria aPL 
recently suggested [2]. Antiphospholipid syndrome (APS) is an autoimmune disease 
characterized by the presence of aPL and at least a clinical event defined as thrombosis 
or pregnancy morbidity [3]. It is called primary or secondary APS according to the 
absence or presence of an underlying connective tissue disorder. The prevalence of aPL 
in the general population is around 5% [4], being transiently positive in cases of 
infections and in any inflammatory state [4;5]. In lupus patients aPL are present in up to 
41% even in the absence of APS [6]. 
According to previous studies [7;8] the titers of aPL frequently decrease and eventually 
become negative during the follow-up period. The negativization has been related with 
a lower risk of thrombotic events, allowing for the possible withdrawal of anticoagulant 
therapy. However, the impact of the negativization on pregnancy morbidities is 
unknown. This fact may have implications regarding the proper management of these 
patients.  
The aim of this study was to explore the clinical and serological course of fertile women 
with positive aPL, as well as the factors and the potential therapeutic implications 




MATERIAL AND METHODS 
Study population 
We conducted a retrospective study which included women attending the obstetric 
autoimmune pathology clinic of a tertiary-facility serving a population of about 550,000 
in Northern Spain. In this clinic, both a gynaecologist and a rheumatologist, attend 
pregnant women with either a previous diagnosis of an inflammatory condition or with 
history of pregnancy morbidities. These patients are tested for antiphospholipid 
antibodies as part of the routine diagnostic work-up. The women included were those 
with a confirmed positive aPL serology according to Sidney Criteria between October 
1995 and December 2013. Laboratory criteria were those of Sydney Criteria: a) LA 
present in plasma, on two or more occasions at least 12 weeks apart, detected according 
to the guidelines of the International Society on Thrombosis and Haemostasis, b) aCL 
of IgG and/or IgM isotype in serum or plasma, present in medium or high titer on two 
or more occasions at least 12 weeks apart, measured by enzyme-linked immunosorbent 
assay (ELISA) or c) aB2GPI of IgG and/or IgM isotype in serum or plasma, present on 
two or more occasions at least 12 weeks apart, measured by ELISA. 
 
Laboratory tests 
IgG and IgM aCL and aB2GPI levels were measured by means of ELISA (Aesku 
diagnostics, Wensdelsheim, Germany) and expressed in GPL or MPL units or U/ml, 
respectively.  Titers were considered to be positive when they were above the 99
th
 
percentile, thus corresponding to 20 GPL, MPL or U/ml.  We considered positive titer 
ranges of (20-30) as medium or high (>30) titers, being low titers considered as negative.  
Lupus anticoagulant was determined according to the standard subcommittee guidelines 
on Lupus Anticoagulant/antiphospholipid antibody (scientific and standardization 
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Committee of the International Society of Thrombosis and Haemostasis) [9]. IgA aCL 
and IgA aB2GPI were not measured, as they are not routinely performed in clinical 
practice and they are not included in the APS classification criteria [3]. 
 
Clinical manifestations 
Thrombotic events, both venous and arterial were analyzed. Pregnancy morbidities 
included in the classification criteria were evaluated. We also analyzed other events not 
included in the Sydney criteria that could be related to aPL such as less than three early 
fetal losses, HELLP syndrome, preeclampsia or eclampsia, abruptio placenta, premature 
birth (<37 weeks), pregnancy hypertension, pregnancy diabetes, early neonatal death 
(<1 week), intrauterine growth restriction and oligohydramnios.  
 
Study groups  
Patients were classified according to 3 different groups: patients with primary APS 
according to Sydney criteria (pAPS); patients with a positive serology for APL, not 
meeting clinical criteria (aPL serology) and patients with Systemic Lupus 
Erythematosus (SLE) according to ACR 1997[10] and a positive aPL serology 
(SLE+aPL).  
We considered time 0 (T0), the date when patient met the serological criteria for APS, 
meaning the second positive aPL result being at least 12 weeks apart from the first one, 
according to Sydney criteria.  We excluded the determinations that were separate less 
than 12 weeks during the first 12 months of follow-up and less than 24 weeks during 
further follow-up. We considered time for negativization the time from the first negative 




The main objective of the study was to describe aPL fluctuations and the rate of 
negativization, and to determine if there were differences among the three study groups.  
Patients were classified, according to the serological aPL evolution into three different 
groups: a) patients with persistently negative aPL  (patients with at least the last 2 
determinations, drawn more than 6 months apart were negative), b) patients with 
transiently positive serology ( patients in which less than two-thirds of the aPL 
determinations were positive) and c) patients with persistently positive serology 
( patients in whom at least two-thirds of the aPL determinations were positive) 
The secondary objectives were a) to identify the clinical and serological risk factors for 
persistently positive aPL serology, as well as its implication in morbidity and mortality 
during the follow-up period; b) to evaluate the impact of treatment withdrawal in those 
with persistently negative aPL and a low-risk profile  (asymptomatic patients, with no 
cardiovascular risk factors and  unwilling to have further pregnancies).   
 
Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics for Windows version 20 
(Armonk, NY: IBM Corp.).  Mean values and standard deviations were calculated for 
the continuous variables. Inter-group differences were analyzed using the Student t-test, 
ANOVA or the chi square tests. A 2-tailed p< 0.05 was considered statistically 
significant. Logistic regression was used to assess factors associated with the 
persistence of positive antibodies.  Kaplan-Meier plots were used to describe the time-





General characteristics of the study population 
We reviewed the clinical charts of 309 patients attending the obstetric autoimmune 
pathology clinic, and finally included 105 female patients meeting inclusion criteria that 
had a confirmed positive aPL serology between October 1995 and December 2013. 
Median age at confirmed serological aPL positivity was 31.8 years (interquartile range 
28.9-36.2).  Of the 105 patients included, 49 patients had pAPS (82% obstetric pAPS, 
14% thrombotic pAPS, and 4% mixed pAPS), 42 patients had a positive serology with 
no clinical criteria of APS (aPL serology), and 14 had SLE with positive aPL 
(SLE+aPL). 
The main characteristics of the study population are shown in supplementary Table 1. 
When comparing the baseline characteristics of the three groups studied, we found no 
differences regarding age and traditional cardiovascular risk factors. The most frequent 
CV risk factor was tobacco use (including current and former smoker) that was present 
in 32 (30.8%) patients. Regarding previous treatments, considering those received 
before T0, the date when patient met the serological criteria for APS, the most common 
therapy used was antiplatelet therapy (48, 46.2%), followed by heparin (17, 16.3%), 
antimalarial drugs (16, 15.4%) and corticosteroids (10, 9.6%). As expected, treatment 
with heparin was more common in the primary APS group (p=0.051) and treatment 
with hydroxychloroquine, steroids, and other immunosuppressants was more frequent in 
lupus patients (p<0.001) (Supplementary Table 1). In line with the immunological 
profile, all patients were tested for aCL and aB2GPI. LA was also determined in 90 
patients out of the 105 patients included. 83% of patients had positive aCL, 71% had 
aB2GPI and 41% had positivity for LA, not finding any differences between the three 
groups. Overall, 35%, 42%, and 23% had positivity for one two and three antibodies, 
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respectively. Moreover, previous thrombotic events and obstetric morbidity were more 
common in the pAPS group. However, pregnancy morbidities not included in the 
classification criteria were more commonly seen in patients with positive serology not 
meeting clinical criteria for APS (p=0.023) (Supplementary Table 2).  
In supplementary table 3 and table 3 we describe the incidence of thrombotic events and 
pregnancy morbidity during follow-up. After a mean follow-up of 114.4 ± 37.2 months 
(range 12-231), 2 patients (1.9%) suffered thrombotic events and 98 women had 174 
new pregnancies. Among them, 21 patients experienced obstetric complications 
classified as Sydney criteria (16 patients had one or more early pregnancy losses, 5 
patients had late pregnancy loss and 3 patients had a live birth with prematurity due to 
preeclampsia, eclampsia or placental insufficiency). A total of 30 patients experienced 
obstetric complications not classified as Sydney criteria being prematurity not related 
with the previous causes (13), oligohydramnios (8), gestational diabetes (6)  and 
intrauterine growth restriction (5) the most frequently seen. There were no differences 
among the 3 groups in the development of further clinical events, although late fetal 
losses were more frequent in pAPS (p=0.050) (Supplementary Table 3). 
 
A significant proportion of fertile women with aPL antibodies became negative 
during follow-up 
Patients were classified into 3 groups according to the positive or negative serology 
during follow-up, as previously described in methods. The mean number of aPL 
determinations was 6.12 ± 3.61, meaning that aPL serum levels were rechecked 6 times 
in every patient. 
After a mean follow-up of 114.4 ± 37.2 months (range 12-231), 62 (59%) patients had 
persistently negative antibodies, 16 (15.2%) patients had transiently positive antibodies, 
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and 27 (25.7%) patients presented persistently positive aPL serology (Table 1). aPL 
turned  negative in 57.1 % of patients with pAPS, in 57.1 % of patients with positive 
serology not meeting clinical criteria of APS and in 71.4 % of lupus patients with 
positive aPL serology (p=0.805). As shown in Table 1 mean age at diagnosis of 
seropositivity was different among the three serological evolution groups (p=0.019), at 
expense of differences between persistently negative and transiently positive serological 
group (Bonferroni posthoc analysis p=0.015). Moreover, smoking was significantly 
more frequent in patients with persistently positive serology (p=0.008). There were not 
any differences regarding other CV risk factors or previous treatment. We did not find 
any differences in previous thrombotic or obstetric events according to the serological 
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Table 1. Traditional cardiovascular risk factors and previous treatments according to the 
















(n = 62) (n=16) (n=27) 
Previous thrombotic 
events, n (%) 
9 (8.6) 4 (6.5) 3 (18.8) 2 (7.4) 0.284 




44 (71) 9 (56.2) 18 (66.7) 0.529 












13 (21) 1 (6.2) 4 (14.8) 0.354 
Table 2. Previous thrombotic and obstetric events according to the serological evolution  
 
Tobacco use and the number of positive antibodies are associated with persistently 
positive serology 
As previously shown we found a clear increased prevalence of smoking in the group 
with persistently positive serology (p=0.008) Table 1. There were no differences when 
analyzing the other traditional CV risk factors, the presence of thrombotic events or 
pregnancy morbidity and previous treatments.  There was a significant difference when 
analyzing the number of positive antibodies (aCL, aB2GPI and LA), with a linear 
association between the number of positive antibodies and the persistence of positive 












Figure 1. Number of positive antibodies (aCL, aB2GPI and LA) according to the 
serological evolution. 
 
We also found that the proportion of smokers was higher in those with triple positivity 
(52.2%) than in those with positivity for one (28.6%) or two antibodies (22.7%) 
(p=0.041). Besides, smoking was also more commonly seen in those patients with 
positivity for LA (41.7% vs 20.8%, p=0.033).  Additionally, we found an association 
between the number of positive antibodies and previous treatment with antimalarial 
drugs ( 2.8% in women with positivity for one antibody, 18.2% in women with 
positivity for two antibodies and 30.4% in women with triple positivity; p=0.004). 
The multivariate analysis using models including the variables with significant 
association in the univariate analysis confirmed that tobacco use was an independent 
risk factor for the persistence of positive serology ( OR=4; 95%CI 1.45-11.08, p=0.008  
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Figure 2. Kaplan Meier Plot of probability of persistently positive serology according 
to tobacco use.  
 
There was also a non-significant trend for association of previous treatment with 
hydroxichloroquine (OR 2.55, 95%CI 0.77-8.47; p =0.125). No other factors reached 
the level of statistical significance.  
 
Patients with persistently positive aPL serology suffer more obstetric 
complications 
No significant differences between the study groups were found regarding the 
development of thrombotic events (Table 3). However, obstetric complications 
included in the Sydney criteria (three or more early fetal losses < 10 weeks, late fetal 
loss >10 weeks or premature birth < 34 weeks due to pre-eclampsia, eclampsia or 
placental insufficiency) were, overall, more frequent in the group of patients with 
persistently positive serology, comparing with those with transiently positive or 





























not find any difference in the frequency of obstetric complications not included in 
Sydney criteria among the serological groups.   
  Total 
number of 
patients 
(n = 105) 
Serological evolution p 
Persistently 
negative 









follow-up (mean ± 
SD) 
1.66±1.01 1.48±0.90 2.06±1.29 1.81±1.00 0.078 
Thrombotic events, n 
(%) 
2 (1.9) 1 (1.6) 1 (6.2) 0 (0) 0.338 
Obstetric events 
included in Sidney 
criteria, n (%) 
21 (20) 9 (14.5) 2 (12.5) 10 (37) 0.036 
Non-criteria obstetric 
events, n (%)  
30 (28.6) 18 (29) 5 (31.2) 7 (25.9) 0.925 
 
Table 3. Thrombotic and obstetric events during follow-up according to the serological 
evolution.  
 
In line with the patients that were diagnosed with APS during follow-up due to obstetric 
morbidity, two belonged to the persistently negative serology group and the other one to 
the persistently positive serology. 
 
Higher number of positive antibodies as well as positivity for lupus anticoagulant 
or anticardiolipin antibodies are associated with the development of further 
obstetric events 
There was a linear association between the number of positive antibodies (aCL,aB2GPI 
and LA) and the obstetric events suffered during follow-up (p=0.033). Figure 3.  
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Figure 3. Frequency of obstetric events according to the number of positive antibodies. 
 
Moreover, patients with LA positivity suffered more obstetric events, both criteria and 
non-criteria, than those without LA (64.9 vs 35.1; p=0.010). Similarly, 48.8% patients 
with aCL developed obstetric events during follow-up, whereas only 22.2% of those 
with negative aCL suffered obstetric events (p=0.066). This tendency was confirmed 
when the analysis was restricted to non-criteria obstetric events where all patients who 
suffered those events had positive aCL (p=0.001). 
 
Treatment withdrawal might be safe in selected patients 
All patients included in the study received antiplatelet or anticoagulant therapy 
previously and/or during follow-up. Among them, 69 were still on treatment at the end 
of the study, in 29 patients treatment was discontinued and in 7 patients information was 
missed.  Regarding the 29 patients in whom antiplatelet therapy was discontinued, 13 
belonged to the pAPS group, 13 had positive serology and 3 had SLE+aPL. All them fit 
the required criteria for antiplatelet therapy discontinuation (aPL were persistently 
negative, patients were asymptomatic for at least 12 months, had no cardiovascular risk 
factors,  and were not willing for further pregnancies). They were all on low-dose 



































followed during a median follow-up of 40.95 months (range 9-135). Three patients were 
excluded due to less than 6 months of follow-up after treatment discontinuation. None 
of them experienced any clinical manifestations related to APS. 
    
DISCUSSION 
There is a scarcity of information about the evolution of aPL serology and its associated 
factors as well as its consequences regarding thrombotic and obstetric events.  We 
studied 105 female patients with a positive aPL serology that were attended in our 
autoimmune obstetric clinic. During almost ten years of follow-up, only 25% remained 
persistently positive, and more than 50% became persistently negative. When analyzing 
possible factors implied, we identified tobacco use as an independent risk factor for 
positivity persistence. Moreover, those women with persistently positive serology were 
at higher risk for further obstetric events, as well as those with a higher number of 
positive antibodies. This finding might have a relevant clinical impact not only on the 
planning of future pregnancies but also to decide the need for long-term antiplatelet 
therapy. 
Martinez-Berriotxoa et al [6] studied a cohort of 237 lupus patients with positive aPL 
serology (excluding positivity for LA) showing that only 10% of patients remained 
persistently positive during follow-up. In contrast, a previous report  by Erkan et al [11], 
showed that aPL remained stable in at least three quarters of subsequent tests, during a 
follow-up period ranging from 1 to 3.5 years depending on the antibody tested. Recently, 
Yelnik et al [12] reported that after a median follow-up of 13 years, 27% of patients had 
a complete aPL disappearance,  aCL being the most commonly negativized, and 
suggesting that triple aPL positivity frequency remained stable over time.  
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It is well known that the levels of aPL fluctuate over time, and many factors have been 
proposed to play a role in such oscillation. Infections, such as CMV [4;13] are 
considered inductors of transient aPL positivity. Pregnancy has also been suggested as 
an inductor of transient aPL by AlBalushi et al [14]. In contrast, Yelnik et al [15] 
showed in a multicenter prospective study a modest decrease in all aPL during the 
course of pregnancy that was not associated with pregnancy outcomes. Overall any 
inflammatory state has been proposed as a promoter of aPL positivity, as suggested in 
SLE patients [16;17]. Some treatments have been proposed to decrease the levels of 
aPL, such as hydroxychloroquine and corticosteroids [18] although other studies did not 
confirm this association [19].  
In our study, we evaluated the clinical factors that could influence the serological 
fluctuations. We found that tobacco use was clearly associated with the persistence of 
positive serology, that could be partially explained as tobacco is considered to be a 
second hit in the pathogenesis of APS [20;21] and has been proposed as an aPL inductor 
in SLE patients [22]. We also described that a higher number of positive antibodies was 
associated with the persistence of positive serology, as previously suggested by 
Gianakoppoulos et al and Yelnik et al[23;24]. However, treatment with 
hydroxychloroquine was not associated with lower probability of persistently positive 
antibodies as previously reported [25;26]. On the contrary, treatment with antimalarials 
was an independent risk factor for positive serology persistence. This fact could be 
explained as treatment with hydroxychloroquine is frequently added in lupus patients 
and also in those refractory APS patients. The fact that antimalarials are used in more 
severe patients, usually with persistently positive serologies, could represent a 
confounding factor that would explain our findings.   
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During follow-up there were 2 thrombotic events. The rate of obstetric complications 
included in the classification criteria decreased from 41.9 % to 20 %, thus reflecting the 
effect of therapy and medical care. These findings are consistent with those reported by 
Cervera et al [27] from the Euro-Phospholipid project that showed an increase in the 
rate of successful pregnancies from 47.6% to 72.9%. The rate of obstetric complications 
included in the classification criteria was shown to be more frequent in those women 
with persistently positive serology than in those with transiently positive or persistently 
negative serology.  To our knowledge, this has not been previously reported in the 
literature. However, similar findings were reported in lupus patients where the risk of 
thrombosis was associated with the presence of positive LA or persistently positive aCL 
[6].  Anyway, patients with persistently negative serology are somehow still at risk for 
thrombotic events, because traditional cardiovascular risk factors and chronic 
inflammation also play a crucial role. Moreover, aPL has been, although not 
consistently, linked to the development of accelerated atherosclerosis. 
We also studied the incidence of obstetric complications that, although not included in 
the classification APS criteria, have been suggested to be associated with the syndrome 
[28-31] such as HELLP syndrome, pre-eclampsia, and intrauterine growth restriction. 
We found that 30 % of patients suffered these complications without any significant 
difference among the clinical or serological groups. This increase in late pregnancy 
morbidities contrasts with the decline in the number of fetal losses and highlights the 
need for multidisciplinary units to guarantee a proper management of these patients, 
especially during the third trimester. 
Recommendations for treatment of APS include indefinite anticoagulation for 
thrombotic APS and low-dose aspirin for obstetric APS. In our study, 29 patients 
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discontinued antiplatelet treatment. All of them were asymptomatic for at least 12 
months, had persistently negative aPL serology, no cardiovascular risk factors and were 
unwilling to have further pregnancies.  They were followed for more than three years, 
showing no thrombotic events. This supports the idea reported by Criado Garcia et al 
[32] that described six patients with primary APS who had persistently negative 
serology and low-risk profile and discontinued anticoagulation showing no recurrence 
of thrombotic events after 21 months of follow-up.   Coloma Bazan et al [33] reported 
similar findings in a series of 11 patients with primary APS and persistently negative 
serology in which thromboprophylaxis was discontinued. 
Our study has some limitations due to the retrospective design of the study. First, some 
data as concomitant risk factors that could influence the presence of aPL antibodies, 
such as obesity, infections or the use of contraceptive drugs were not systematically 
reported in the clinical charts. Also in some patients data regarding the date of 
antiplatelet therapy discontinuation was missing. Finally, the follow-up was not 
homogeneous among the group of patients. However, the high number of patients 
included in the study, the homogeneity of the population studied, as well as the long 
duration of follow-up support our original results with clear clinical implication.  
In summary, our study suggests that among fertile women, aPL remains persistently 
positive in only one-quarter of patients. In these patients with persistently positive 
serology, tobacco use was identified as an independent risk factor for this persistence. 
The persistence of aPL serology is associated with pregnancy morbidity, treatment with 
antiplatelet therapy being efficient in decreasing early pregnancy complications. 
However, late pregnancy morbidity is still frequent thus supporting the need for 
multidisciplinary units for monitoring these patients. In patients with persistently 
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negative serology and with a low-risk thrombotic profile discontinuation of antiplatelet 
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